Alcobra To Provide Corporate Overview At 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

Published: Jan 31, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, 2014. The Alcobra presentation is on Monday, February 10 at 3:30pm Eastern Time.

Help employers find you! Check out all the jobs and post your resume.

Back to news